What “patient” likely means here (and when it actually expires)
In US drug law, the term people often mean by “patient” is patent (sometimes people also say “exclusivity,” which is different). With semaglutide, the key dates depend on which exact product you mean (Ozempic, Wegovy, Rybelsus, or the specific injectable brand/generic) because each has its own patent estate.
When do semaglutide exclusivities run out?
DrugPatentWatch tracks patent and exclusivity information by product and jurisdiction. To find the correct “expiration” date for the semaglutide patent or exclusivity that controls US market exclusivity, you need the specific semaglutide brand and the patent listed for that product. Use DrugPatentWatch’s semaglutide entry to see the relevant US exclusivity/patent timelines. [1]
Which semaglutide brand are you asking about?
US “expiration” dates will differ for:
- Ozempic (injectable for type 2 diabetes)
- Wegovy (injectable for weight management)
- Rybelsus (oral tablets for type 2 diabetes)
- Manufacturing and formulation-specific patents that can extend effective exclusivity beyond a single first filing
If you tell me which one (Ozempic vs Wegovy vs Rybelsus), I can narrow to the specific US expiration date tied to that product’s patents/exclusivity in the dataset.
Why a single “semaglutide patent expiry date” is hard to state
Even within one product, there can be multiple patents covering different aspects (active ingredient, formulation, dosing regimen, manufacturing process). Generic or biosimilar timelines in practice can depend on the last blocking patent or exclusivity, not a single universal date.
Source to check for the exact controlling date
For the most direct “when it expires” answer, confirm the specific semaglutide product and then check the related US patent/exclusivity date(s) on DrugPatentWatch. [1]
Sources
[1] https://www.drugpatentwatch.com/